The settlement followed government intervention in a qui tam suit alleging Alphama paid kickbacks in the form of sham consulting arrangements, payments for attendance at meetings and so-called educational grants in order to increase sales of Kadian, a morphine-based drug, according to the release.
Read the release on the Alpharma settlement.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.